The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma.
Xiaoyun Zhang,Xinrui Zhu,Chang Liu,Wusheng Lu,Qiu Li,Weixia Chen,Zhiping Li,Qiang Lu,Wei Peng,Chuan Li,Lvnan Yan,Jiayin Yang,Tianfu Wen
DOI: https://doi.org/10.1200/jco.2022.40.4_suppl.453
IF: 45.3
2022-01-21
Journal of Clinical Oncology
Abstract:453 Background: More than 70% of hepatocellular carcinoma (HCC) patients are in the intermediate or advanced stages at the time of diagnosis. TACE, TKI and PD-1 antibody are all recommended for patients with unresectable HCC (uHCC) according to Chinese HCC guidelines. There are few scientific trials to back up the safety and effecacy of TACE+TKI+PD-1 antibody for the treatment of uHCC and conversion resection. In this study, we explored the safety and efficacy of the TACE+TKI+PD-1 antibody in uHCC. Methods: This is a prospective, multicenter, cohort study (NCT04997850). Key Eligibility Criteria:18 years old ≤ age ≤ 70 years old; HCC confirmed by histopathology or cytology; No systemic treatment history. ECOG PS score 0-1; Child-Pugh A/B; BCLC stage B/C.Experience group: TACE + Lenvatinib (12mg when≥ 60kg/8mg when < 60kg QD) + Camrelizumab/ Sintilimab (200 mg ivgtt Q3W);Control group: TACE. Results: From Sep 2020 to May 2021, 38 patients were enrolled in experimental group (Table). At the cutoff date (Sep 10 2021), the median follow-up was of 33.34 weeks (Table). The conversion resection rate was 50% (19/38), and the conversion success rate was 52.6% (20/38). Among the 19 patients, 5 cases achieved complete pathological response and 1 case achieved major pathological response. The 48 weeks' OS rate and PFS were 96.4% (95%CI 92.9% to 99.9%) and 91.7%(95%CI 85.8% to 97.4%).22 patients had level 3 treatment related adverse events (TRAE), there were no level 4 and 5 TRAEs. At the last follow-up, the ORR rate based on mRECIST was 84.2%, and the DCR rate was 94.7% (Table). Conclusions: TACE + Lenvatinib + PD-1 antibody is safe and effective, and conversion resection after the triple-treatment is feasible for uHCC. Clinical trial information: 04997850. Baseline characteristics, adverse events and clinical outcomes (N=38) Baseline Characteristics Gender, male, n (%) 35(92.1%) Bodyweight, kg, median, (range) 62(45-90) Etiology, [HBV/HCV/Non-HBV/HCV, n (%)] 29(76.3%)/1(2.6%)/8(21.1%) ECOG PS, [0/1, n (%)] 36(94.7%)/2(5.3%) AFP level, ng/ml, median(range) 353(0.91-470518) DCPlevel,mAU/mL,median(range) 6274(32-75000) BCLC stage, [B/C, n (%)] 9(23.7%)/29(76.3%) Tumor numbers, [1/2/3, n (%)] 19(50%)/15(39.5%)/4(10.5%) Treatment Related Adverse Events (TRAE), n (%) Any Adverse Events 100(100%) Most common TRAEs(≥50% of patients) Abdominal pain 27(71.1%) Aspartate aminotransferase increased 25(65.8%) Alanine aminotransferase increased 25(65.8%) Hypertension 22(57.9%) ≥Grade 3 TRAEs 22(57.9%) RAE leading to drug reduction 3(7.9%) TRAE leading to drug conclusions 0(0%) Clinical Outcomes mRECIST ORR 32(84.2%) CR/PR/SD/PD 6(15.8%)/26(68.4%)/4(10.5%)/2(5.3%)
oncology